Literature DB >> 421410

Factors influencing plasma concentrations of ethosuximide.

G A Smith, L McKauge, D Dubetz, J H Tyrer, M J Eadie.   

Abstract

The relation between steady-state plasma ethosuximide level and drug dose was studied in 46 patients. In this population, plasma drug levels were proportional to drug dose, expressed on a body weight basis. Age did not alter this relationship, but plasma levels increased more rapidly, relative to dose, in females than in males. Intake of methylphenobarbitone, but not intake of certain other anticonvulsants (phenytoin, phenobarbitone, primidone and carbamazepine) altered the relationship between plasma ethosuximide level and ethosuximide dose. In individual patients, successive dose increments of equal size produced progressively greater increases in steady-state plasma ethosuximide levels. This phenomenon has obvious therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 421410     DOI: 10.2165/00003088-197904010-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  9 in total

1.  The absorption and excretion of ethosuximide.

Authors:  R A Buchanan; A W Kinkel; T C Smith
Journal:  Int J Clin Pharmacol       Date:  1973-04

2.  The simultaneous determination of multiple anticonvulsant drug levels by gas-liquid chromatography. Method and clinical application.

Authors:  E B Solow; J B Green
Journal:  Neurology       Date:  1972-05       Impact factor: 9.910

3.  Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.

Authors:  N Gerber; J G Wagner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-05

4.  Ethosuximide blood levels in epileptics.

Authors:  A F Haerer; R A Buchanan; F M Wiygul
Journal:  J Clin Pharmacol J New Drugs       Date:  1970 Nov-Dec

5.  Factors influencing plasma phenobarbitone levels in epileptic patients.

Authors:  M J Eadie; C M Lander; W D Hooper; J H Tyrer
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Ethosuximide dosage regimens.

Authors:  R A Buchanan; A W Kinkel; J L Turner; J C Heffelfinger
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

8.  Ethosuximide in the treatment of absence (peptit mal) seizures.

Authors:  T R Browne; F E Dreifuss; P R Dyken; D J Goode; J K Penry; R J Porter; B G White; P T White
Journal:  Neurology       Date:  1975-06       Impact factor: 9.910

9.  Relative frequency of different types of epilepsy: a study employing the classification of the International League Against Epilepsy.

Authors:  H Gastaut; J L Gastaut; G E Gonçalves e Silva; G R Fernandez Sanchez
Journal:  Epilepsia       Date:  1975-09       Impact factor: 5.864

  9 in total
  6 in total

Review 1.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 2.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

4.  Ethosuximide plasma concentrations: influence of age and associated concomitant therapy.

Authors:  D Battino; C Cusi; S Franceschetti; A Moise; S Spina; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

Review 5.  A Practical Guide to Treatment of Childhood Absence Epilepsy.

Authors:  Sudha Kilaru Kessler; Emily McGinnis
Journal:  Paediatr Drugs       Date:  2019-02       Impact factor: 3.022

Review 6.  Therapeutic Options for Childhood Absence Epilepsy.

Authors:  Victoria Elisa Rinaldi; Giuseppe Di Cara; Elisabetta Mencaroni; Alberto Verrotti
Journal:  Pediatr Rep       Date:  2021-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.